Search results
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks· 23 hours agoEli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 days agoThe Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with AstraZeneca during BIO International ...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 6 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 5 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 6 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
Democrats ramp up patent fight with drug industry in bid to lower prices
Washington Post· 12 hours agoDemocrats have hit on a new tactic in their long battle with drug companies: challenge patents that...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WSAU Wausau· 5 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 5 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
Germany’s Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions – Interview
The Wall Street Journal· 16 hours agoMerck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop...